T h e binding sites on human IgGl for human Fc y receptor (FcyR) I, FcyRIIa, FcyRIIb, FcyRIIIa and neonatal FcR have been mapped. A common set of I g G l residues is involved in binding to all FcyRs, while FcyRII and FcyRIII utilize distinct sites outside this common set. In addition to residues which abrogated binding to the FcyR, several positions were found which improved binding only to specific FcyRs or simultaneously improved binding to one type of FcyR and reduced binding to another type. Selected I g G l variants with improved binding to FcyRIIIa were then tested in an in vitro antibody-dependent cellular cytotoxicity (ADCC) assay and showed an enhancement in ADCC when either peripheral blood mononuclear cells or natural killer cells were used.
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Monoclonal antibodies (mAbs) elicit four main effector functions : antibody-dependent cellular cytotoxicity (ADCC), phagocytosis, complementdependent cytotoxicity and half-life/clearance rate. ADCC and phagocytosis are mediated through interaction of cell-bound mAbs with Fc y receptors (FcyRs), complement-dependent cytotoxicity by interaction of cell-bound mAbs with the complement system, and half-life by binding of free mAbs to the neonatal Fc receptor (FcRn) . In addition to ADCC and phagocytosis, FcyRs play a critical role in linking other mAb-mediated immune responses with cellular effector functions, including release of inflammatory mediators, endocytosis of immune complexes and regulation of immune system cell activation [l-31. For mAbs that recruit the immune system to kill a target cell, engineering the IgG Fc portion to improve effector function (through improved binding to FcyR, FcRn and/or complement) could be a valuable enhancement to antibody therapeutics.
In some cases a full-length mAb is required for long half-life, but other effector functions may be unnecessary or even deleterious. Immune system recruitment can be ablated by using human IgG2 or IgG4 subclasses, altering IgG residues in the hinge or other regions of the Fc [ 4 9 ] , or using antibody F(ab) or F(ab'), fragments (though these may have rapid clearance rates). Absence of the carbohydrate attached to Asn-297 (Eu numbering scheme [lo] ) of the Fc also reduces binding of IgG to FcyRs and complement [8, FcyRs are expressed on immune system effector cells [e.g. natural killer ( N K ) cells, neutrophils, monocytes/macrophages, B-cells] and comprise three classes : FcyRI (CD64), FcyRII (CD32) and FcyRIII (CD16). In humans, the latter two classes are further divided into FcyRIIa and FcyRIIb, FcyRIIIa and FcyRIIIb. T h e receptors differ in their affinity for IgG, e.g. FcyRI exhibits a high affinity for monomeric I g G l whereas FcyRII and FcyRIII exhibit a relatively weak affinity for monomeric I g G l and hence can only interact effectively with multimeric immune complexes. T h e complexity of the human FcyR system is amplified by the presence of polymorphic forms of the receptors. FcyRIIa has two forms, Arg-13 1 and His-1 3 1, that differ in binding of IgG2 [16] . FcyRIIIa has polymorphisms at positions 48 (Leu/His/Arg) and 158 (Phe/Val), though only the latter has been reported to effect a binding and biological difference [ 17-1 91. FcyR-I I I b polymorphic forms N A l and NA2 differ in four amino acids [20] . Possible clinical significance involving polymorphic forms for all three receptors has been reported [21-241.
T h e binding sites on human I g G l for human FcyRI, FcyRIIa, FcyRIIb, FcyRIIIa and FcRn have been mapped [8] . All solvent-exposed residues in human I g G l Fc were individually altered to alanine and each variant tested for binding to the different receptors. One group of I g G l residues reduced binding to all FcyRs when altered to alanine: Pro-238, Asp-265, Asp-270, Asn-297 (loss of Fc carbohydrate) and Pro-329. All are in the IgG CH2 domain and clustered near the hinge joining CH1 and C H 2 ; these residues, in conjunction with the hinge region (residues 216-238), previously shown to affect FcyR binding [4] [5] [6] , comprise the set of IgGl residues utilized in binding all FcyRs.
While FcyRI utilizes only the common set of IgGl residues for binding, FcyRII and FcyRIII interact with distinct residues in addition to the common set. Alteration of some residues reduced binding only to FcyRII (e.g. Arg-292) or FcyRIII (e.g. Glu-293). Unexpectedly, a number of variants showed improved binding to FcyRII or FcyRIII but did not affect binding to the other receptor (e.g. Ser-267Ala improved binding to FcyRII but binding to FcyRIII was unaffected; Figure 1 ). Other variants exhibited improved binding to FcyRII or FcyRIII with reduction in binding to the other receptor (e.g. Ser-298Ala improved binding to FcyRI I I and reduced binding to FcyRII; Figure 1 ). IgGl variants in which two or more residues were simultaneously altered to alanine exhibited additivity [8]. For FcyRIIIa, the best-binding IgGl variants combined alanine substitutions at Ser-298, Glu-333 and Lys-334; Ser-298Ala/Glu-333Ala, Ser-298Ala/ Lys-334Ala and Ser-298Ala/Glu-333Ala/Lys334Ala all bound greater than 1.5-fold more strongly than native IgGl in an ELISA-format assay. These variants exhibited a more pronounced improvement in binding to the FcyRIIIa(Phe-158) polymorph compared with the FcyRIIIa(Va1-158) polymorph. Though 1 .5-fold might seem small, these variants also showed enhanced in vitro ADCC using purified human peripheral blood mononuclear cells or NK cells as effector cells. As with the ELISA-format binding assay, the increase in ADCC was more pronounced for effector cells from FcyRIIIa(Phe-158/Phe-158) donors than those from FcyRIIIa(Val-158/Val-158) donors [8] (Figure 2) .
Studies comparing mice with and without specific FcyRs have shown that for some therapeutic mAbs the presence of FcyR is necessary for efficacy [25-281. Though recruitment of the immune system to destroy the target cell could be the mechanism (via ADCC, phagocytosis or other pathways), it is also possible that in some cases the FcyR-bearing cells might function only as crosslinking agents. A full-length mAb can cross-link two target molecules as a consequence of its inherent bivalency, though additional cross-linking of cell-bound mAbs may enhance their function [29] . Rituximab, a chimaeric anti-CD20 mAb for non-Hodgkin's lymphoma, requires cross-linking of CD20-bound mAb to effect efficient apoptosis of B-cells [30, 31] . In vitro, cross-linking can be achieved using anti-human IgG-specific mAbs ; in vivo, though, either FcyR-bearing cells or C l q must act as a cross-linking agent. When an IgG4 [33] . An IgG receptor involved in maintaining IgG homoeostasis in blood has been hypothesized [34] , but only recently has a specific receptor been proposed to fulfil this role-the FcRn. In addition to regulating homoeostasis, FcRn controls transcytosis across tissues [35] . This receptor is structurally related to M H C class I, comprising an a-chain that non-covalently associates with p2-microglobulin [36] . The IgG-FcRn interaction is pH-dependent, with IgG binding at p H 6 but not at pH 7.2 (the p H of blood), an observation integrated into a current model of how FcRn functions [35] . form of Rituximab was evaluated in monkeys it
Many of the studies on FcRn have utilized the had no effect, whereas the IgGl form was efficamurine receptor. The epitope on murine IgG cious [32] . From this experiment alone one cannot for murine FcRn has been mapped [35] . Notably, discern whether FcyR and/or C l q act as alteration of specific residues in murine IgG that the necessary cross-linking agent because IgG4 does not bind well to either. However, in a study comparing wild-type and FcyRIIFcyRI I Iknockout mice, Rituximab lost most of its efficacy in the knockout mice, suggesting that FcyRbearing cells are the major, if not only, crosslinking agent.
Regarding IgGl variants with improved binding to FcyR, though these variants have not yet been tested in vivo, three important possibilities exist. First, if a therapeutic mAb utilizes FcyR-bearing cells as part of its mechanism of action (either as cross-linking agent or to elicit ADCC or phagocytosis), then mAbs with improved binding to FcyR (compared with native IgG) could exhibit increased efficacy. Second, IgG variants that have enhanced binding to activating FcyRs (FcyRI, FcyRIIa and/or improve binding to murine FcRn also effect an increased half-life in mice [37] . T h e epitope on human IgGl for human FcRn has also been mapped and substituting specific IgGl residues with alanine enhanced binding to FcRn [8] . The range of improvement in binding to human FcRn by alteration of individual IgGl residues was 1.4-to 3 .5-fold. Individual substitutions to alanine could be combined to further increase binding to FcRn up to 12-fold. Notably, these alterations improved binding only at p H 6.0, but not pH 7.2 [8] , and therefore would not hinder dissociation of the IgG from FcRn. Hence, the half-life of therapeutic mAbs may be able to be extended by a varying degree dependent on which IgGl amino acids are altered or in which combination. In some instances, it might be advantageous to either decrease or prolong the half-life, e.g. the latter could conceivably reduce the dosage or frequency of administration without affecting the efficacy.
Finally, many of the IgGl residues that are involved in binding to FcyRs and FcRn are different. As a consequence, it is possible to generate IgGl variants with altered FcyR-binding characteristics (improved or debilitated) and altered half-life (prolonged or shortened). For example, if a therapeutic mAb required enhanced ADCC (or cross-linking ability) and a longerthan-normal half-life, a Ser-298Ala/Glu-333AIa/ Lys-334Ala/Asn-434AIa IgGl variant might suffice. If a therapeutic mAb with ablated FcyR binding but longer-than-normal half-life was needed, an Asp-265Ala/Asn-434AIa IgGl variant could be used. 
